combination NRT

ApprovedSmall molecule

UUniversity of Alabama at Birmingham

combination NRT is one of 79 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Smoking CessationActive, not recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

Smoking CessationApproved

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

combination NRT

UUniversity of Alabama at Birmingham

Approved

1 2

Tecentriq

Roche

Preclinical

36 3

Adriamycin

GGynecologic Oncology Group

Preclinical

87 4

Gemzar

GGynecologic Oncology Group

Preclinical

22 5

DATROWAY

Daiichi Sankyo

Preclinical

4 6

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 7

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 8

Lipegfilgrastim

Merck & Co.

Preclinical

1 9

Promestriene

UUniversity of Sao Paulo General Hospital

Preclinical

1 10

Citalopram Hydrobromide

TTorrent Pharmaceuticals Limited

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Post-ApprovalRecruiting

Smoking Cessation

NCT06598397

Clinical

Trials by Indication[1]

Smoking Cessation2 trials

Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care

Recruiting·NNew York University·Phase 4·NCT06598397·500 enrolled

Genetically Informed Smoking Cessation Trial

Completed·WWashington University School of Medicine·Phase 4·NCT02351167·822 enrolled

Breast Cancer1 trial

Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

Completed·UUniversity of Alabama at Birmingham·N/A·NCT02158507·20 enrolled

Non-Small Cell Lung Cancer1 trial

Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer

Completed·UUniversity of Alabama at Birmingham·Phase 1·NCT00476216·23 enrolled

Medication Adherence1 trial

Nicotine Replacement Therapy (NRT) Sampling and Selection to Increase Medication Adherence

Completed·UUniversity of Alabama at Birmingham·Phase 4·NCT03276780·80 enrolled

Effectiveness1 trial

A Comparative Effectiveness RCT of Optimized Cessation Treatments

Completed·UUniversity of Wisconsin, Madison·Phase 4·NCT02301403·623 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for combination NRT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — combination NRT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for combination NRT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Alabama at Birmingham company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Alabama at Birmingham

combination NRT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Smoking Cessation2 trials

Breast Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Medication Adherence1 trial

Effectiveness1 trial

References

Drug Info

Quick Facts

Related News